Case Report: Three Patient Responses to Ivosidenib for Cholangiocarcinoma

Three detailed case studies illustrate the clinical use of ivosidenib for patients with cholangiocarcinoma harboring IDH1 mutations. The document, authored by Yannick Buccella and shared under a CC-BY-4.0 license, includes data on treatment duration, tumor response, and patient-specific challenges. It was last updated on June 2, 2026, and references outcomes from the phase 3 ClarIDHy clinical trial.

Use Cases

• Analyze real-world treatment outcomes and response durability based on the detailed patient narratives.
• Study the management of treatment challenges in older or frail patients as described in the case studies.
• Investigate the implications of co-occurring mutations (e.g., IDH1 and HER2) on treatment decisions.
• Review the role of early molecular testing and biopsy adequacy in treatment pathway planning as highlighted in the report.

Strengths

• Includes specific clinical outcomes, such as a 2-year survival rate of 92% for responders with >1 year of treatment.
• Provides concrete, illustrative examples of rare events, like tumor shrinkage seen in only 2% of patients in the referenced trial.
• Released under a permissive CC-BY-4.0 license, allowing for broad reuse and sharing.

Limitations

• The dataset is a single 144.7 KB PDF document containing three case reports, representing a very limited sample size.
• Row count and column-level documentation are absent; the data is presented in narrative form rather than a structured, machine-readable format.
• Freshness should be verified; the last update date is in the future (2026-06-02), which may indicate a placeholder or error.

Provenance

Source

Yannick Buccella via figshare.

Collection Method

Clinical case report compilation.

Freshness

Last updated 2026-06-02 13:00:08; freshness should be verified.